BLANDIZZI, CORRADO
 Distribuzione geografica
Continente #
NA - Nord America 804
EU - Europa 460
AS - Asia 266
OC - Oceania 24
SA - Sud America 9
AF - Africa 3
Totale 1.566
Nazione #
US - Stati Uniti d'America 802
RU - Federazione Russa 338
HK - Hong Kong 111
SG - Singapore 67
PL - Polonia 44
CN - Cina 38
IN - India 32
IT - Italia 27
AU - Australia 24
IE - Irlanda 22
SE - Svezia 11
BR - Brasile 7
FI - Finlandia 7
ID - Indonesia 6
DE - Germania 4
VN - Vietnam 4
KR - Corea 3
CA - Canada 2
CI - Costa d'Avorio 2
ES - Italia 2
JO - Giordania 2
AR - Argentina 1
AT - Austria 1
AZ - Azerbaigian 1
DK - Danimarca 1
FR - Francia 1
GB - Regno Unito 1
JP - Giappone 1
NG - Nigeria 1
NL - Olanda 1
PE - Perù 1
PH - Filippine 1
Totale 1.566
Città #
Santa Clara 571
Hong Kong 108
Singapore 56
Warsaw 44
Moscow 28
Mumbai 23
Dublin 22
Fairfield 21
Melbourne 19
Shanghai 19
Chandler 18
West Jordan 14
Ashburn 11
Cambridge 10
Wilmington 10
Woodbridge 9
Florence 7
Helsinki 6
Houston 6
Jakarta 6
Seattle 6
Altamura 5
Lawrence 5
Sydney 5
Chennai 4
Dong Ket 4
Princeton 4
Rome 4
Bhubaneswar 3
Boston 3
Buffalo 3
Los Angeles 3
Abidjan 2
Barcelona 2
Chicago 2
New York 2
São Paulo 2
The Dalles 2
Alagoinhas 1
Andover 1
Baku 1
Beijing 1
Berlin 1
Boardman 1
Bremen 1
Buenos Aires 1
Castelliri 1
Chandigarh 1
Fuyang 1
Genova 1
Grosseto 1
Guarulhos 1
Guelph 1
Hangzhou 1
Jacksonville 1
Kagoya 1
Kunming 1
Lagos 1
Lima 1
Livorno 1
London 1
Manila 1
Norwalk 1
Nova Friburgo 1
Nuremberg 1
Pisa 1
Portland 1
Romola 1
Rui'an 1
San Diego 1
Seongnam 1
Simões Filho 1
São Simão 1
Toronto 1
Vienna 1
Totale 1.106
Nome #
Clinical differences among the elderly admitted to the emergency department for accidental or unexplained falls and syncope 149
Deepening the Mechanisms of Visceral Pain Persistence: An Evaluation of the Gut-Spinal Cord Relationship 125
Hepatitis C virus infection: opportunities for an earlier detection in primary care 97
Adverse drug reactions in oncoLogy: intEnsive monitoring program on drug toXicity of biotechnological medicatioNs anD taRget therapies in Oncologic patientS - the ALEXANDROS observational study 76
Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy 68
Trajectories of use of biologic disease modifying antirheumatic drugs in rheumatoid arthritis: A cohort study of Tuscan patients, Italy 64
Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy) 63
The Economic Impact of the Introduction of Infliximab-Biosimilar: Preliminary Results from a Study on Rheumatologic Patients in Tuscany, Italy 61
Trajectories of adherence to biologic disease-modifying anti-rheumatic drugs in tuscan administrative databases: The pathfinder study 60
THE ECONOMIC IMPACT OF THE INTRODUCTION OF INFLIXIMAB-BIOSIMILAR: AN EMPIRICAL ANALYSIS USING THE TUSCANY HEALTHCARE ADMINISTRATIVE DATABASES 59
Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis 59
Trajectories of oral budesonide use in Crohn's disease cohort of Tuscan patients (Italy) 58
Direct health care costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study 58
Time to biologic treatment and to total colectomy associated with diagnostic delay in ulcerative colitis: Analysis of an Italian regional administrative healthcare database 57
The Anti-TNF Drugs and the Risk of Lymphoma, Skin Cancer and Melanoma: A Signal Detection Analysis 57
Switching from infliximab-originator to infliximab-biosimilar in rheumatologic patients: The clinical impact in Tuscan Region, Italy 56
Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients 55
Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy 55
Recommendations by the Tuscan Health Authority to Use Infliximab-Biosimilar in the Clinical Practice: Safety Impact 55
Validation test for algorithms to identify rheumatoid arthritis patients in the Tuscan healthcare administrative databases 55
Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases 54
Longitudinal adherence trajectories to biologic disease modifying anti-rheumatic drugs in Tuscany, Italy 52
Utilization patterns and healthcare accesses of JAKi used in rheumatoid arthritis patients in Tuscany: The LEONARDO study 52
Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons 51
Totale 1.596
Categoria #
all - tutte 4.911
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.911


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20208 0 0 0 0 0 0 0 0 4 2 1 1
2020/202179 2 6 4 16 4 10 4 10 5 10 2 6
2021/202221 1 0 0 2 1 1 0 2 1 4 3 6
2022/202382 7 12 4 9 8 12 10 11 7 1 1 0
2023/2024183 0 5 3 23 4 7 4 62 6 36 5 28
2024/20251.184 39 137 82 173 408 264 6 64 11 0 0 0
Totale 1.596